Here's How Sanofi Hopes to Survive Post-Lantus

Sanofi (SNY) hopes its promising new diabetes drug U300 will protect its top line when Lantus loses patent protection in 2015.

Mar 27, 2014 at 2:30PM

Sanofi's (NYSE:SNY) Lantus is the globe's best selling diabetes drug, generating more than $7.5 billion in revenue last year. Lantus makes up 17% of Sanofi's global sales and has posted two consecutive years of nearly 20% growth.

However, Lantus' market dominance in diabetes -- its sales outpace therapies from Novo (NYSE:NVO) and Eli Lilly (NYSE:LLY) -- may wane given patent protection for the compound expires in 2015. To blunt the expiration impact, Sanofi is developing U300, a Lantus successor that is posting solid results in late-stage trials.

SNY Chart

SNY data by YCharts.

Targeting a big and growing market
The market for diabetes treatment is massive. More than 365 million people worldwide suffer from the disease, roughly half of whom are unaware they have it. The vast majority -- nearly 80% -- of diabetics live in low and middle income countries, which means roughly 70 million diabetics live in developed countries with established access to therapies like Lantus.

The enormous size of the diabetes market makes it the biggest in terms of spending. According to Express Scripts' Drug Trend Report, $79 per member per year was spent by payers on diabetes therapy in 2012. That's nearly 20% more than was spent on cholesterol treatments -- the second highest disease in terms of treatment cost.

Spending on diabetes therapies is expected to climb significantly over the next 20 years given the global population of diabetics is estimated to eclipse 550 million by 2030. That represents a large market opportunity for new treatments, especially when investors consider Lantus' megablockbuster status reflected just 7% of all diabetes spending in 2012.

The next generation of diabetes drugs
Drug developers are advancing a series of next-generation diabetes therapies designed to better control blood glucose levels. While the opportunity for this new class of drugs is big, these new therapies don't pose much of a direct threat to Lantus.

Lantus is a once-daily, long acting insulin that doesn't compete with short-term insulin therapies like Novo's Novalog, which has more than 40% market share among rapid-acting insulin,or Lilly's Humalog, which had sales of $2.6 billion last year.

Lantus doesn't directly compete against newly launched GLP-1 drugs like Novo's Victoza and SGLT2 inhibitors like Johnson & Johnson's (NYSE:JNJ) Invokana, either. 

GLP-1 drugs mimic or encourage activity of a key hormone released by the intestines to promote insulin production that helps regulate blood glucose levels. GLP-1 drugs include Novo's Victoza and AstraZeneca's (NYSE:AZN) Byetta and Bydureon. Novo's Victoza, approved in 2010, is already producing $300 million in quarterly sales for Novo, and AstraZeneca's sales of Byetta and Bydureon totaled about $1 billion in 2013.

SGLT2 drugs target the SGLT2 protein in the kidney responsible for aiding in the reabsorption of glucose. By blocking the kidney's ability to reabsorb glucose, drugs like Invokana and AstraZeneca's Forxiga help blood glucose levels fall given more glucose is eliminated through patient urine. Industry watchers think Invokana, which won FDA approval a year ago, could eventually achieve peak sales of more than $2 billion. AstraZeneca's Forxiga, which won the FDA green light in January, will battle for market share this year, too. 

Since GLP-1 and SGLT2 drugs work differently than long-acting insulin, they're often prescribed alongside, rather than instead of, Lantus.

Replacing Lantus
Lantus' upcoming patent expiration is increasing the pressure to launch a successor, and Sanofi hopes that successor will be a new and improved version of Lantus named U300.

Sanofi has been conducting late-stage trials comparing U300 against Lantus in an attempt to prove U300 is as good as -- and safer -- than Lantus.  So far, results have been solid.

Interim phase 3 data released last June demonstrated U300 does a better job controlling nighttime glucose levels than Lantus. That's important given poor nighttime control can impact patient quality of life and, in extreme cases, can be deadly.

Those results were confirmed in December when Sanofi reported 23% fewer patients taking U300 had low nighttime blood sugar levels than those taking Lantus. The study also showed U300 did a better job controlling blood sugar levels in the daytime, too.

Fool-worthy final thoughts
Sanofi filed a lawsuit to block Lilly's Lantus biosimilar in January. That bought U300 more time to win approval and garner market share given Lilly's copycat will likely be delayed by the suit until at least 2016.

Sanofi expects to submit U300 to U.S. and EU regulators for approval in the second quarter, suggesting U300 has an opportunity to start adding meaningfully to Sanofi's results in 2015. That won't give U300 much time to gain a foothold before biosimilars arrive, but since U300 patients appear to have fewer glycemic events, I think that there's a good chance doctors will embrace it, and the Lantus revenue stream will be protected.

Diabetes is just one market trend -- here are three stocks that could become your next huge winner
The one sure way to get wealthy is to invest in a groundbreaking company that goes on to dominate a multibillion-dollar industry. Our analysts have done it before with great biotech stocks. And now they think they've done it again with three stock picks that they believe could generate the same type of phenomenal returns. They've revealed these picks in a new free report that you can download instantly by clicking here now.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B.Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers